Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc
Bullboard Posts
User Avatar Image
(1)
•••
Comment by TrueNorth911on Dec 12, 2018 11:31pm
69 Views
Post# 29107492

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Upset, dissapointed and betrayed.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Upset, dissapointed and betrayed. I would think you're right regarding the other $4.5M from Fosun coming soon....  Not sure what/when they are allowed to report on trials?   I'll take $10 by end of January as a nice stop on our way to $50 some day soon!

I recall when a LOT of people were pancking and selling AMAZON at $25 many years ago.... all so SMART and SMUG that they knew better than anyone else.... well, I didn't panick then, and certainly not now either. 

Good luck to All!




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities